Long-term course of ambulatory patients with COVID-19 initially treated with enoxaparin vs no anticoagulation: final analysis of the OVID (enoxaparin for outpatients with COVID-19) randomized trial.

Riccardo M FumagalliDavide VociBehnood BikdeliRoland BingisserGiuseppe ColucciGabor ForgoTeresa GerardiBernhard GerberAlexandru GrigoreanFrederikus A KlokMarc RighiniHelia Robert-EbadiStefan StorteckySilvia UlrichSimon WolfDörte WyssLukas HobohmNils KucherStefano Barconull null

Published in: Research and practice in thrombosis and haemostasis (2024)

Early thromboprophylaxis does not improve long-term, 2-year clinical and functional outcomes among symptomatic ambulatory patients with acute COVID-19.

Keyphrases

venous thromboembolism
coronavirus disease
sars cov
blood pressure
direct oral anticoagulants
atrial fibrillation
respiratory syndrome coronavirus
newly diagnosed